- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Further information:
- Topic in appraisal
- Process:
- STA Standard
- ID number:
- 6439
Provisional Schedule
- Committee meeting:
- 08 October 2025
- Expected publication:
- 17 December 2025
Project Team
- Project lead
- Jeremy Powell
Email enquiries
If you have any queries please email [email protected]
- External Assessment Group:
- School of Health and Related Research (ScHARR), University of Sheffield
Stakeholders
- Companies sponsors
- Astra Zeneca
- Others
- Department of Health and Social Care
- NHS England
- Patient carer groups
- Kidney Care UK
- Kidney Research UK
- Muslim Council of Great Britain
- National Kidney Federation
- Pumping Marvellous Foundation
- South Asian Health Foundation
- Specialised Healthcare Alliance
- Professional groups
- Association of Renal Technologists
- British Association of Endocrine and Thyroid Surgeons
- British Cardiovascular Society
- British Geriatrics Society
- British Renal Society
- British Society for Heart Failure
- National Metabolic Biochemistry Network
- Renal Association
- Royal College of General Practitioners
- Royal College of Nursing
- Royal College of Pathologists
- Royal College of Physicians
- Royal Pharmaceutical Society
- Royal Society of Medicine
- Society for Endocrinology
- UK Clinical Pharmacy Association
- UK Renal Pharmacy Group
- Associated public health groups
- Public Health Wales
- UK Health Security Agency
- Comparator companies
- none
- General commentators
- All Wales Therapeutics and Toxicology Centre
- Allied Health Professionals Federation
- Board of Community Health Councils in Wales
- British National Formulary
- Care Quality Commission
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- National Association of Primary Care
- National Pharmacy Association
- NHS Confederation
- Scottish Medicines Consortium
- Welsh Government
- Welsh Health Specialised Services Committee
- Relevant research groups
- Cochrane Metabolic & Endocrine Disorders Group
- Genomics England
- MRC Clinical Trials Unit
- National Institute for Health Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 11 April 2025 | Due to an unforeseen change in External Assessment Group (EAG) availability, the timelines for this appraisal have been revised. The first committee meeting will now be held on 8 October 2025. |
| 25 October 2024 | Invitation to participate |
| 25 October 2024 | In progress. Final scope issued. |
| 28 August 2024 - 11 September 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 31 May 2024 | Awaiting development |
For further information on our processes and methods, please see our CHTE processes and methods manual